India & Moderna

India: India has generously donated emergency pharmaceutical supplies to the United States — Centers for Disease Control and Prevention to aid in the Ebola response in the Democratic Republic of the Congo, demonstrating its commitment to global health security.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

India: India is highlighted as the leading country of origin for immigrant founders of US billion-dollar companies, demonstrating its significant contribution to the American startup ecosystem.

Moderna: Moderna is an immigrant-founded unicorn company that has gone public since 2016.

India: India is on high alert due to the Ebola virus outbreak in Africa, with its Central Government advising against non-essential travel to affected countries and monitoring suspected cases.

Moderna: Moderna is one of the groups receiving funding to develop an Ebola vaccine, indicating potential future market opportunities.

India: India is partnering with the United States — Centers for Disease Control and Prevention to deliver medical supplies to aid in the Ebola response.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

India: India, along with the African Union, postponed the India-Africa Forum Summit due to the evolving health situation in parts of Africa, demonstrating the international repercussions of the Ebola outbreak.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

India: India is a potential market, with media coverage and potential patient impact.

Moderna: Moderna is the developer of the mRNA vaccine and the primary beneficiary, with its stock surging over 120% and market cap increasing by nearly $40 billion. The trial success validates its mRNA platform beyond COVID-19 and could lead to a new revenue stream.

India: Home to Serum Institute of India, manufacturing vaccine doses. Its role is in vaccine production.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.